Mark Kay, M.D., Ph.D.

Dr. Kay is the Head of the Division of Human Gene Therapy and the Associate Chair of Research in Pediatrics at Stanford University. Dr. Kay’s research addresses the scientific principles of gene and nucleic acid transfer for the treatment of genetic and acquired diseases. He is a scientific founder of Voyager Therapeutics and LogicBio Therapeutics. Dr. Kay serves on the board of the Oligonucleotide Therapeutics Society and is founding member and previous president of the American Society for Gene Therapy. Dr. Kay was honored as 2013 Researcher of the Year by the National Hemophilia Foundation and is the recipient of the American Society for Gene and Cell Therapy 2013 Outstanding Investigator Award. Dr. Kay has published over 250 peer-reviewed articles.

‹ Back